Aims: To define the number/frequency of organ systems affected by extraintestinal manifestations (EIMs), to identify factors affecting the clinical course of inflammatory bowel disease (IBD) and EIM development, and to determine the impact of smoking, disease duration and location on the diagnosis of EIMs in Crohn's disease (CD) and ulcerative colitis (UC). Methods: IBD patients were derived from a single university colorectal surgery practice. Smoking data were obtained through a modified Behavioral Risk Factor Surveillance System survey. The frequencies of arthritis/arthralgia, primary sclerosing cholangitis (PSC), ocular and cutaneous EIMs were determined. Results: Of the 757 patients evaluated (CD 488, UC 269), 50% had ≥1 EIM. Arthritis/arthralgia, cutaneous and ocular EIMs were significantly higher in frequency in CD compared to UC patients. Prolonged disease duration was associated with increased prevalence of arthritis/arthralgia in IBD (p ≤ 0.001) as well as PSC (p = 0.049), ocular (p = 0.030) and cutaneous (p = 0.009) EIMs in CD. Disease location affected the occurrence of EIMs in CD. Smoking appeared to increase the prevalence of ocular EIMs in UC (p = 0.026). Conclusion: Arthritis/arthralgia, cutaneous and ocular EIMs occurred in a significantly higher proportion of CD patients. CD patients with longer disease duration had a significantly higher prevalence of PSC, ocular and cutaneous EIMs. Smoking was found to increase ocular EIMs in UC.

Journal Section:
Original Paper
Keywords:
Extraintestinal manifestations, Crohn’s disease, Ulcerative colitis, Cigarette smoking
1.
Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-1517.
[PubMed]
https://doi.org/10.1053/j.gastro.2004.01.063
2.
Lakatos PL, Szalay F, Tulassay Z, Molnar T, Kovacs A, Gasztonyi B, Papp J, Lakatos L: Clinical presentation of Crohn's disease. Association between familial disease, smoking, disease phenotype, extraintestinal manifestations and need for surgery. Hepatogastroenterology 2005;52:817-822.
[PubMed]
3.
Martins NB, Peppercorn MA: Inflammatory bowel disease. Am J Manag Care 2004;10:544-552.
[PubMed]
4.
Newman B, Siminovitch K: Inflammatory bowel disease: Crohn's disease and the success of NODern genetics. Clin Invest Med 2003;26:303-314.
[PubMed]
5.
Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A: Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227-7236.
[PubMed]
6.
Farmer RG, Hawk WA, Turnbull RB Jr: Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975;68:627-635.
[PubMed]
7.
Greenstein AJ, Janowitz HD, Sachar DB: The extraintestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976;55:401-412.
[PubMed]
https://doi.org/10.1097/00005792-197609000-00004
8.
Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr: National cooperative Crohn's disease study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914-920.
[PubMed]
9.
Gasche C, Schober E, Turetschek K: Small bowel barium studies in Crohn's disease. Gastroenterology 1998;114:1349.
[PubMed]
https://doi.org/10.1016/S0016-5085(98)70454-8
10.
Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, Vader JP, Michetti P: Extraintestinal manifestations of Crohn's disease. Digestion 2007;76:141-148.
[PubMed]
https://doi.org/10.1159/000111029
11.
Su CG, Judge TA, Lichtenstein GR: Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:307-327.
[PubMed]
https://doi.org/10.1016/S0889-8553(01)00019-X
12.
Calkins BM: A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989;34:1841-1854.
[PubMed]
https://doi.org/10.1007/BF01536701
13.
Mahid SS, Minor KS, Stevens PL, Galandiuk S: The role of smoking in Crohn's disease as defined by clinical variables. Dig Dis Sci 2007;52:2897-2903.
[PubMed]
https://doi.org/10.1007/s10620-006-9624-0
14.
Odes HS, Fich A, Reif S, Halak A, Lavy A, Keter D, Eliakim R, Paz J, Broide E, Niv Y, Ron Y, Villa Y, Arber N, Gilat T: Effects of current cigarette smoking on clinical course of Crohn's disease and ulcerative colitis. Dig Dis Sci 2001;46:1717-1721.
[PubMed]
https://doi.org/10.1023/A:1010609722315
15.
Tuvlin JA, Raza SS, Bracamonte S, Julian C, Hanauer SB, Nicolae DL, King AC, Cho JH: Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts. Inflamm Bowel Dis 2007;13:573-579.
[PubMed]
https://doi.org/10.1002/ibd.20043
16.
Manguso F, Sanges M, Staiano T, Gargiulo S, Nastro P, Gargano D, Somma P, Mansueto G, Peluso R, Scarpa R, D'Armiento FP, Astarita C, Ayala F, Renda A, Mazzacca G, D'Arienzo A: Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol 2004;99:327-334.
[PubMed]
https://doi.org/10.1111/j.1572-0241.2004.04039.x
17.
Ricart E, Panaccione R, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ: Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004;10:207-214.
[PubMed]
https://doi.org/10.1097/00054725-200405000-00005
18.
Mahid SS, Minor KS, Stromberg AJ, Galandiuk S: Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis 2007;13:431-438.
[PubMed]
https://doi.org/10.1002/ibd.20070
19.
Remington PL, Smith MY, Williamson DF, Anda RF, Gentry EM, Hogelin GC: Design, characteristics, and usefulness of state-based behavioral risk factor surveillance: 1981-87. Public Health Rep 1988;103:366-375.
[PubMed]
20.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753.
[PubMed]
https://doi.org/10.1136/gut.2005.082909
21.
Van der Heide F, Dijkstra A, Albersnagel FA, Kleibeuker JH, Dijkstra G: Active and passive smoking behaviour and cessation plans of patients with Crohn's disease and ulcerative colitis. J Crohns Colitis 2010;4:125-131.
[PubMed]
https://doi.org/10.1016/j.crohns.2009.09.005
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.